These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 35036076)

  • 1. MerTK-mediated efferocytosis promotes immune tolerance and tumor progression in osteosarcoma through enhancing M2 polarization and PD-L1 expression.
    Lin J; Xu A; Jin J; Zhang M; Lou J; Qian C; Zhu J; Wang Y; Yang Z; Li X; Yu W; Liu B; Tao H
    Oncoimmunology; 2022; 11(1):2024941. PubMed ID: 35036076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting MerTK decreases efferocytosis and increases anti-tumor immune infiltrate in prostate cancer.
    Myers Chen KV; de Groot AE; Mendez SA; Mallin MM; Amend SR; Pienta KJ
    Med Oncol; 2023 Aug; 40(10):284. PubMed ID: 37644281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1.
    Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX
    J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential polarization and the expression of efferocytosis receptor MerTK on M1 and M2 macrophages isolated from coronary artery disease patients.
    Mohd Idrus FN; Ahmad NS; Hoe CH; Azlan M; Norfuad FA; Yusof Z; Wan Isa WYH; Mohamed Ali AA; Yvonne-Tee GB
    BMC Immunol; 2021 Mar; 22(1):21. PubMed ID: 33761885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 6. IL-17A/IL-17RA interaction blockade sensitizes synovial macrophages to efferocytosis and PD-L1 signaling via rewiring STAT-3/ADAM17/MERTK axis in rheumatoid arthritis animal model.
    Samarpita S; Srivastava S; Srikanth M; Miriam Jose A; Rithvik A; Rasool M
    Int Immunopharmacol; 2024 Jul; 136():112343. PubMed ID: 38810305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blockade of the Phagocytic Receptor MerTK on Tumor-Associated Macrophages Enhances P2X7R-Dependent STING Activation by Tumor-Derived cGAMP.
    Zhou Y; Fei M; Zhang G; Liang WC; Lin W; Wu Y; Piskol R; Ridgway J; McNamara E; Huang H; Zhang J; Oh J; Patel JM; Jakubiak D; Lau J; Blackwood B; Bravo DD; Shi Y; Wang J; Hu HM; Lee WP; Jesudason R; Sangaraju D; Modrusan Z; Anderson KR; Warming S; Roose-Girma M; Yan M
    Immunity; 2020 Feb; 52(2):357-373.e9. PubMed ID: 32049051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombospondin-1 induced programmed death-ligand 1-mediated immunosuppression by activating the STAT3 pathway in osteosarcoma.
    Liu Z; Wen J; Hu F; Wang J; Hu C; Zhang W
    Cancer Sci; 2022 Feb; 113(2):432-445. PubMed ID: 34927311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibiting efferocytosis reverses macrophage-mediated immunosuppression in the leukemia microenvironment.
    Cruz Cruz J; Allison KC; Page LS; Jenkins AJ; Wang X; Earp HS; Frye SV; Graham DK; Verneris MR; Lee-Sherick AB
    Front Immunol; 2023; 14():1146721. PubMed ID: 36960055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin II deteriorates advanced atherosclerosis by promoting MerTK cleavage and impairing efferocytosis through the AT
    Zhang Y; Wang Y; Zhou D; Zhang LS; Deng FX; Shu S; Wang LJ; Wu Y; Guo N; Zhou J; Yuan ZY
    Am J Physiol Cell Physiol; 2019 Oct; 317(4):C776-C787. PubMed ID: 31390228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity.
    Lee-Sherick AB; Jacobsen KM; Henry CJ; Huey MG; Parker RE; Page LS; Hill AA; Wang X; Frye SV; Earp HS; Jordan CT; DeRyckere D; Graham DK
    JCI Insight; 2018 Nov; 3(21):. PubMed ID: 30385715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between PD-1/PD-L1 expression and polarization in tumor-associated macrophages: A key player in tumor immunotherapy.
    Li W; Wu F; Zhao S; Shi P; Wang S; Cui D
    Cytokine Growth Factor Rev; 2022 Oct; 67():49-57. PubMed ID: 35871139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment-Induced Tumor Cell Apoptosis and Secondary Necrosis Drive Tumor Progression in the Residual Tumor Microenvironment through MerTK and IDO1.
    Werfel TA; Elion DL; Rahman B; Hicks DJ; Sanchez V; Gonzales-Ericsson PI; Nixon MJ; James JL; Balko JM; Scherle PA; Koblish HK; Cook RS
    Cancer Res; 2019 Jan; 79(1):171-182. PubMed ID: 30413412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A+T rich interaction domain protein 3a (Arid3a) impairs Mertk-mediated efferocytosis in cholestasis.
    Chen R; Huang B; Lian M; Wei Y; Miao Q; Liang J; Ou Y; Liang X; Zhang H; Li Y; Xiao X; Wang Q; You Z; Chai J; Gershwin ME; Tang R; Ma X
    J Hepatol; 2023 Dec; 79(6):1478-1490. PubMed ID: 37659731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. YAP/STAT3 inhibited CD8
    Wang C; Shen N; Guo Q; Tan X; He S
    Cancer Med; 2023 Aug; 12(15):16295-16309. PubMed ID: 37329188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RNA-based modulation of macrophage-mediated efferocytosis potentiates antitumor immunity in colorectal cancer.
    Zhou X; Li D; Xia S; Ma X; Li R; Mu Y; Liu Z; Zhang L; Zhou Q; Zhuo W; Ding K; Lin A; Liu W; Liu X; Zhou T
    J Control Release; 2024 Feb; 366():128-141. PubMed ID: 38104775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efferocytosis is restricted by axon guidance molecule EphA4 via ERK/Stat6/MERTK signaling following brain injury.
    Soliman E; Leonard J; Basso EKG; Gershenson I; Ju J; Mills J; de Jager C; Kaloss AM; Elhassanny M; Pereira D; Chen M; Wang X; Theus MH
    J Neuroinflammation; 2023 Nov; 20(1):256. PubMed ID: 37941008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer.
    Diskin B; Adam S; Cassini MF; Sanchez G; Liria M; Aykut B; Buttar C; Li E; Sundberg B; Salas RD; Chen R; Wang J; Kim M; Farooq MS; Nguy S; Fedele C; Tang KH; Chen T; Wang W; Hundeyin M; Rossi JAK; Kurz E; Haq MIU; Karlen J; Kruger E; Sekendiz Z; Wu D; Shadaloey SAA; Baptiste G; Werba G; Selvaraj S; Loomis C; Wong KK; Leinwand J; Miller G
    Nat Immunol; 2020 Apr; 21(4):442-454. PubMed ID: 32152508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib inhibits doxorubicin-induced PD-L1 upregulation to improve immunosuppressive microenvironment in Osteosarcoma.
    Wang J; Hu F; Yu P; Wang J; Liu Z; Bao Q; Zhang W; Wen J
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):5127-5138. PubMed ID: 36348018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AIM2 fosters lung adenocarcinoma immune escape by modulating PD-L1 expression in tumor-associated macrophages via JAK/STAT3.
    Ye H; Yu W; Li Y; Bao X; Ni Y; Chen X; Sun Y; Chen A; Zhou W; Li J
    Hum Vaccin Immunother; 2023 Dec; 19(3):2269790. PubMed ID: 37877820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.